Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Levine on Combos With PARP Inhibitors in Ovarian Cancer

February 4th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses what potential PARP inhibitors could have with chemotherapy regimens as a treatment for patients with ovarian cancer.

Dr. Muggia on the GOG 252 Trial in Ovarian Cancer

February 2nd 2017

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses the GOG 252 trial, which looked at the use of intravenous versus intraperitoneal chemotherapy in the treatment of patients with ovarian cancer.

Laparoscopy Plays Predictive Role for Primary Surgery Outcomes in Ovarian Cancer

January 28th 2017

Diagnostic laparoscopy reduced the number of futile laparotomies in patients with suspected advanced-stage ovarian cancer, according to the results of a recent study.

Study Explores Correlations Among Irregular Menstrual Cycles, PCOS, and Ovarian Cancer Risk

January 27th 2017

Long or irregular menstrual cycles may be a marker of an increased risk for developing certain subtypes of ovarian cancer, according to the results of a recent study.

Expert Discusses Uncertainty Over Ideal IP Chemo Approach in Ovarian Cancer

January 23rd 2017

Franco M. Muggia, MD, discusses the results of the Gynecologic Oncology Group (GOG) 252 trial and what the findings mean regarding intraperitoneal therapy for patients with ovarian cancer.

Future Directions for Treating Advanced Ovarian Cancers

January 20th 2017

Ongoing PARP Inhibitor Research in Ovarian Cancer

January 20th 2017

Differences Among PARP Inhibitors in Ovarian Cancer

January 20th 2017

Sequencing Therapies for Ovarian Cancer

January 20th 2017

Niraparib Maintenance Therapy for Ovarian Cancer

January 20th 2017

Rucaparib for Ovarian Cancer

January 20th 2017

PARP Inhibitors for Ovarian Cancer: Use of Olaparib

January 20th 2017

Bevacizumab for Recurrent Ovarian Cancer

January 20th 2017

Recurrent Ovarian Cancer; Considerations Beyond the Platinum-Free Interval

January 20th 2017

Dose-Dense Chemotherapy for Ovarian Cancer; Adding Bevacizumab

January 20th 2017

Intravenous vs Intraperitoneal Chemotherapy for Ovarian Cancer

January 20th 2017

Surgical Management of Advanced Ovarian Cancer

January 20th 2017

When to Refer to Genetic Counseling

January 20th 2017

BRCA Testing for Ovarian Cancer

January 20th 2017

Classification of Ovarian Cancers

January 20th 2017